ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 0246 • ACR Convergence 2025

    Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS

    Marco Di Paola1, Fiorella Anna Lombardi1, Edmund J MacLaughlin2, Maurizio Muratore3, Kathleen Methric4, Gianmarco Del Vecchio5, Giusy Peluso6, Chiara Stomaci7, Roberto Franchini1, Francesco Conversano1, Paola Pisani1 and Sergio Casciaro1, 1Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, 2Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, 3ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, 4BoneVue Diagnostics, Catonsville, MD, 5Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, 6Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, 7Department of Biological and Envinronmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy

    Background/Purpose: Intestinal Bowel Diseases (IBD), including Crohn’s (ChD), and Ulcerative Colitis (UCD), along with Celiac (ClD), diseases are chronic inflammatory conditions that primarily affect the…
  • Abstract Number: 0139 • ACR Convergence 2025

    When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?

    Santiago Dans Caballero1, Massimo Radin2, Chary López pedrera3, MARIA ANGELES AGUIRRE ZAMORANO4, Christian Merlo-Ruiz5, Ismael Sanchez-Pareja4, Irene Cecchi6 and Savino Sciascia7, 1Reina Sofia University Hospital, Lebrija, Andalucia, Spain, 2University of Turin, Turin, Turin, Italy, 3Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, 4Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 5Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, 6University of Turin, Turin, Piemonte, Italy, 7University of Turin, Torino, Italy

    Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…
  • Abstract Number: 0024 • ACR Convergence 2025

    Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease

    Daniel Panyard1, Daniel Li2, Pik Fang Kho2, Rodrigo Guarischi-Sousa3, Jiayan Zhou2, Austin Hilliard4, Christie Bartels5, Philip Tsao2 and Themistocles Assimes2, 1Stanford University, Sunnyvale, CA, 2Stanford University, Palo Alto, CA, 3Palo Alto Veterans Institute for Research, Palo Alto, CA, 4VA Palo Alto Health Care, Palo Alto, CA, 5University of Wisconsin School of Medicine and Public Health, Madison, WI

    Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
  • Abstract Number: 2641 • ACR Convergence 2025

    Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases

    Ricardo Grieshaber-Bouyer1, Jamie Haddon2, Maria Gabriella Raimondo3, Carlo Tur3, Sebastian Böltz3, Tobias Dashi4, Melanie Hagen5, Andreas Wirsching3, Tobias Rathe4, Xuan Wu6, Peter Wung2, Francis Kim2, Yonghong Zhu6, Ken Song2, Timothy Lu7 and Georg Schett8, 1University Hospital Erlangen, Erlangen, Germany, 2Candid Therapeutics, San Diego, CA, 3Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 4Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 5Friedrich-Alexander-University Erlangen-Nuremberg, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, 6EpimAb Biotherapeutics, Shanghai, China (People's Republic), 7Candid Therapeutics, San Diego, 8Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany

    Background/Purpose: Emerging data show the potential of T-cell engagers (TCEs) for deep B cell depletion to treat autoimmune diseases. Cizutamig is a purposefully designed BCMAxCD3…
  • Abstract Number: 2538 • ACR Convergence 2025

    Comparative Study of Two Classification Criteria Sets in Real Clinical Practice in Behçet’s Disease

    Rafael Gálvez Sánchez1, José Luis Martín-Varillas2, Lara Sánchez Bilbao3, Ivan Ferraz Amaro4, Carmen Lasa Teja5, Elena Aurrecoechea6, Diana Prieto-Peña7 and Ricardo Blanco3, 1Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, 2Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, 3Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 4Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 5Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, 6Hospital Sierrallana, CANTABRIA, Spain, 7Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain

    Background/Purpose: Behçet´s Disease (BD) was traditionally classified according to the International Study Group (ISG) in which oral ulcers were mandatory. International Team for the Revision…
  • Abstract Number: 2417 • ACR Convergence 2025

    Anti-dense fine speckled 70 antibodies in undefined disease, systemic autoimmune rheumatic diseases and controls

    Rammohan Mylavarapu1, Meghna Gavali2, Bansi Kashyap Parijeya3, Kaushik Puranam4 and Liza rajasekhar5, 1NIZAMS INSTITUTE OF MEDICAL SCIENCES, Hyderabad, Telangana, India, 2nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, 3Synergy superspeciality hospital, Rajkot, Gujarat, India, 4Nizams Institute Of Medical Sciences , Hyderabad, hyderabad, Telangana, India, 5Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

    Background/Purpose: Systemic autoimmune rheumatic diseases (SARD) are a heterogeneous group of disorders marked by the presence of antinuclear antibodies (ANA), commonly detected by HEp-2 cell-based…
  • Abstract Number: 2050 • ACR Convergence 2025

    Efficacy and Safety of Antifibrotic Therapy in Autoimmune–Associated Interstitial Lung Disease: A Meta-Analysis

    Sri Laxmi Priya Sunkara1, Ravi Medarametla2, Anjani Mahesh Kumar Cherukuri3, Rithish Nimmagadda4, Kaksha Parrikh5, Punith Chirumamilla6, Pranathi Bandarupalli7, Manoja Gullapalli8 and Naga Alekhya Garikipati9, 1White river medical center, batesville, AR, 2Mamata Medical College, Guntur, Andhra Pradesh, India, 3Guntur Medical College, Guntur, Andhra Pradesh, India, 4One Brooklyn Health, New York, NY, 5Atlanticare regional medical center, New Jersey, 6Baptist Memorial Hospital North Mississippi, Oxford, MS, 7Mercy St Vincent Medical Center, Toledo, OH, 8University of Arkansas for Medical Sciences, Little Rock, AR, 9Mediciti Institute Of Medical Sciences, Hyderabad, India

    Background/Purpose: Autoimmune–associated interstitial lung disease (A‑ILD) which includes Rheumatoid arthritis associated interstitial lung disease (RA-ILD), Systemic Sclerosis associated interstitial lung disease (SS-ILD), and others is…
  • Abstract Number: 1869 • ACR Convergence 2025

    A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease

    Olga Sanchez Pernaute1, Mª Jesus Rodriguez-Nieto2, Cristina Vadillo Font3, Maria asuncion Nieto3, Laura Cebrian4, Belen Lopez Muñiz5, Hilda Godoy Tundidor6, Rosalia Laporta7, Jesus Loarce Martos8, Juan A Rigual8, fredeswinda Romero-Bueno9, Irene Llorente Cubas10, Claudia Valenzuela10, Gema Bonilla11, Luis Gomez Carrera12, Rosario Garcia Vicuña13, Ana Jaureguizar8, Jose Luis Morell Hita8 and lydia Abasolo Alcazar14, 1Clinica Universidad de Navarra, Madrid, Madrid, Spain, 2Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, 3Hospital Clínico S Carlos, Madrid, Spain, 4Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, 5Hospital Universitario Infanta Leonor, Madrid, Spain, 6Hospital Universitario puerta de hierro, Madrid, Spain, 7Hospital Puerta de Hierro Majadahonda, Madrid, Spain, 8Hospital Ramón y Cajal, Madrid, Spain, 9University Hospital Fundación Jiménez Díaz"", Madrid, Spain, 10Hospital Universitario Princesa, Madrid, Spain, 11Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, 12Hospital Universitario La Paz, Madrid, Spain, 13Hospital Universitario de la Princesa, Madrid, Spain, 14IdISSC. HCSC, Madrid, Madrid, Spain

    Background/Purpose: Patients with interstitial lung disease associated to a connective tissue disease (CTD-ILD) are a heterogeneous population both concerning mechanisms and trajectories. In an RNA…
  • Abstract Number: 1728 • ACR Convergence 2025

    Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study

    Jiana Chen1, Jiaqi Xu1, Ziyue Zhou2, Xu Jiang1 and Huaxia Yang1, 1Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, the Ministry of Education Key Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100730, Beijing, China, Beijing, China (People's Republic), 2peiking meidical, beijing

    Background/Purpose: Immune checkpoint inhibitors (ICIs), while revolutionary in cancer treatment, may induce severe or even fatal immune-related adverse event (irAE). The mechanisms underlying irAE development…
  • Abstract Number: 1547 • ACR Convergence 2025

    Anifrolumab In Systemic Lupus Erythematosus With Renal Involvement: National Multicenter Registry In Clinical Practice

    Vanesa Calvo-Río1, Carmen Secada-Gómez1, Blanca Garcia-Magallon2, Deseada Palma-Sanchez3, Andrea García-Valle4, Irati Urionaguena Onaindia5, Adrián Mayo-Juanatey6, Paúl Hernández Velasco7, GUILLERMO GONZALEZ ARRIBAS8, Ana Pareja-Martínez9, Montserrat Corteguera10, Guillen Sada Urmeneta11, Paz Collado Ramos12, Jose Luis Tandaipan13, Juan Roberto Miguelez Sanchez14 and Ricardo Blanco1, 1Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 2Rheumatology. Hospital Universitario Puerta de Hierro, Madrid, Spain, 3Rheumatology. Hospital Rafael Méndez, Lorca, Murcia, Spain, 4Rheumatology. Hospital General Río Carrión, Palencia, Castilla y Leon, Spain, 5Rheumatology.Hospital Galdakao, Vizcaya, Pais Vasco, Spain, 6Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 7Nephrology, Hospital Universitario 12 de Octubre, Madrid. Spain, Madrid, Madrid, Spain, 8Facultativo especialista, PALMA DE MALLORCA, Galicia, Spain, 9Rheumatology. Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain, 10Rheumatology. Complejo Asistencial de Ávila, Ávila, Castilla y Leon, Spain, 11Rheumatology. Hospital Reina Sofía, Tudela, Navarra, Spain, 12Department of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain,, MADRID, Madrid, Spain, 13Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, 14Department of Rheumatology, Hospital Universtiario de Móstoles, Madrid, Spain, Madrid, Madrid, Spain

    Background/Purpose: Lupus Nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), occurring in up to 50% of patients. Currently, Anifrolumab (ANI) is approved…
  • Abstract Number: 1431 • ACR Convergence 2025

    Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort

    SUBIN PHILIP1, RITESH KUMAR MISHRA2, RIZWANA NAUSHAD1, Lovely Kumari3, Vishnu Koneru4, Aishwarya Gopal5, Christina Mariaselvam6, Chengappa Kavadichanda7, Ananthakrishnan Ramesh1, Molly Thabah1 and VIR SINGH NEGI1, 1JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, 2JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, 3Jawaharlal Institute of Postgraduate Medical Education and Research,PUDUCHERRY, PUDUCHERRY, Puducherry, India, 4JIPMER, Hyderabad, Telangana, India, 5Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Pondicherry, Puducherry, India, 6Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, Puducherry, India, 7Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India

    Background/Purpose: Axial involvement in psoriatic arthritis (PsA) is variable and influences treatment choices. Data on axial PsA in Indian patients, especially its clinical and radiographic…
  • Abstract Number: 1269 • ACR Convergence 2025

    Dress for success: Influence of Rheumatologist Demographics and Attire on Patients with Chronic Inflammatory Arthritis Perceptions

    LETICIA LEON1, LAURA CANO2, ELENA MORENO3, GABRIELA CASTILLO4, GUIDO CORRADI5, MARTA REDONDO4, MARIA ISABEL CASADO5, DALIFER FREITES6, ALMUDENA TRUCHARTE4, INMACULADA UREÑA2 and lydia Abasolo Alcazar7, 1Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, 2Hospital Regional Universitario de Málaga, MALAGA, Andalucia, Spain, 3Fundación Investigación Biomédica Hospital Clínico San Carlos, MADRID, Madrid, Spain, 4Universidad Camilo Jose Cela, MADRID, Madrid, Spain, 5Universidad Complutense de Madrid, MADRID, Madrid, Spain, 6Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, 7IdISSC. HCSC, Madrid, Madrid, Spain

    Background/Purpose: Physician sociodemographic factors and attire has been shown to influence patients’ trust. This study aimed to determine differences on patient perceptions of rheumatologist professionalism,…
  • Abstract Number: 1122 • ACR Convergence 2025

    A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-Related Problems

    William Koch1, Donald Anthony2, Janeen Leon2 and Nora G. Singer2, 1University Hospitals Parma Medical Center, Parma, OH, 2The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH

    Background/Purpose: Janus kinase (JAK) inhibitors are immunosuppressive medications that target the JAK-STAT signaling pathway. Tofacitinib (Xeljanz) was the first JAK inhibitor approved for the treatment…
  • Abstract Number: 0990 • ACR Convergence 2025

    An Fc-engineered Agonistic Anti-PD-1 Antibody Selectively Depletes PD-1+ cells and Attenuates T cell activation in vitro and in vivo in a Xenogeneic Graft-versus-Host Disease (GvHD) model

    laetitia Pouzol, Patrizia Murer, Nicole Egli, Laetitia Petersen, Anais Zurbach, christian Stocker, alexander Rau, andreas Katopodis and christoph huber, Anaveon, Basel, Switzerland

    Background/Purpose: PD-1+ T cells play a pivotal role in the pathogenesis of autoimmune diseases, including rheumatoid arthritis. Therapeutic antibodies targeting PD-1 with both depleting and…
  • Abstract Number: 0929 • ACR Convergence 2025

    SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice

    Martin Jakobsen1, Pernille Noer2, Kristina Byskov3, Emil Nilsson4, Laura Ryø5, Claus Olesen2 and Richard BETHELL6, 1Aarhus University, Aarhus, Denmark, 2Sulis Therapeutics, Aarhus, Denmark, 3Notify Therapeutics, Aarhus, Denmark, 4Sulis Therapeutics, Aarhus C, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Sulis Therapeutics, Stockholm, Sweden

    Background/Purpose: STING plays a critical role at the intersection of innate and adaptive immunity and has been linked to the pathogenesis of SSc and SLE.…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology